To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.7594565.
Little is known about real-world use of small molecule kinase inhibitors (SMKI) for advanced thyroid cancer in the United States. This study examined prescribing patterns of SMKI agents recommended by the National Comprehensive Cancer Center (NCCN).
This retrospective study used a national health insurance database to identify patients diagnosed with thyroid cancer during 1/1/2006–6/30/2016 and with prescription claims for NCCN-recommended SMKI during 1/1/2010–5/31/2016 whose first claim date was the index date. Inclusion also required continuous enrollment in a health plan for 3 months pre-index (baseline) and ≥ 1 month post-index (follow-up) with no claims for SMKI during baseline. Lines of therapy (LOT) were defined by the date of SMKI claims and days of drug supply. Median time to SMKI discontinuation in each LOT was estimated by Kaplan–Meier method.
The study included 217 patients. During follow-up (mean duration 499.0 days), 35.5% of patients (n = 77) received a second or later LOT; among patients with ≥ 12 months follow-up after first LOT (LOT1) initiation, 53.1% (n = 60) received a second or later LOT. Median treatment duration was 5.0 months for LOT1 and 5.1 months for LOT2. Over the entire follow-up period (2010–2016), sorafenib was the most common regimen in LOT1 (36.9% of patients) and LOT2 (24.7%) followed by sunitinib and levantinib (13.4% each) in LOT1 and sunitinib (19.5%) in LOT2. Starting in 2015, the year lenvatinib was approved for differentiated thyroid cancer, lenvatinib was the most common first-line regimen among patients initiating LOT1 in 2015 (43.4%) and 2016 (66.7%).
Sorafenib was the most common first-line agent during 2010–2014 but was supplanted by lenvatinib starting in 2015. Approximately 36–53% of patients received a second-line treatment. Median treatment duration results suggested potential benefit of SMKI in second-line therapy. SMKI treatment after first-line failure may be considered for appropriately selected patients.
Eisai, Inc. (Woodcliff Lake, NJ).
American Cancer Society. Cancer facts & figures 2018. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf. Accessed 29 Oct 2018.
Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. CrossRef
Howlader N, Noone A, Krapcho M, et al. SEER cancer statistics review, 1975–2014, National Cancer Institute. Bethesda, MD, based on November 2016 SEER data submission, posted to the SEER web site, April 2017. https://seer.cancer.gov/csr/1975_2014/sections.html. Accessed 29 Oct 2018.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines). Thyroid carcinoma. v.2.2017-May 17, 2017 https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 20 Nov 2017.
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133. CrossRefPubMedPubMedCentral
Nexavar (sorafenib) tablets [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc; 2017. http://labeling.bayerhealthcare.com/html/products/pi/Nexavar_PI.pdf. Accessed 29 Oct 2018.
Lenvima (lenvatinib) capsules [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; 2018. http://www.lenvima.com/pdfs/prescribing-information.pdf. Accessed 29 Oct 2018.
Caprelsa (vandetanib) tablets [prescribing information]. Cambridge, MA: Genzyme Corporation; 2016. http://www.caprelsarems.com/files/caprelsa-pi.pdf?v=2.0. Accessed 29 Oct 2018.
Cometriq (cabozantinib) capsules [prescribing information]. South San Franciso, CA: Exelixis Inc; 2016. https://cometriq.com/downloads/Cometriq_Full_Prescribing_Information.pdf. Accessed 29 Oct 2018.
Smith JC, Medalia C. U.S Census Bureau, current population reports, P60-253. Health Insurance Coverage in the United States: 2014 https://www.census.gov/content/dam/Census/library/publications/2015/demo/p60-253.pdf. Accessed 11 Apr 2018.
Agency for Healthcare Research and Quality. Clinical classification software (CCS) for ICD-9-CM. https://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp. Accessed 17 Dec 2018.
Pilon D, Behl AS, Ellis LA, Emond B, Lefebvre P, Dawson NA. Duration of treatment in prostate cancer patients treated with abiraterone acetate or enzalutamide. J Manag Care Spec Pharm. 2017;23(2):225–35. PubMed
Schultz NM, Flanders SC, Wilson S, et al. Treatment duration, healthcare resource utilization, and costs among chemotherapy-naive patients with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate: a retrospective claims analysis. Adv Ther. 2018;35(10):1639–55. CrossRefPubMedPubMedCentral
- Real-World Treatment Patterns Among Patients Initiating Small Molecule Kinase Inhibitor Therapies for Thyroid Cancer in the United States
Stacey A. Dacosta Byfield
Prashant R. Joshi
Francis P. Worden
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Sommerakademie-Visual, Mail Icon II